Skip Navigation

Cardiovascular Research 2006 69(1):4-6; doi:10.1016/j.cardiores.2005.11.017
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Abdallah, Y.
Right arrow Articles by Schäfer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdallah, Y.
Right arrow Articles by Schäfer, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Insulin: An overall cardiovascular protector?

Yaser Abdallah* and Claudia Schäfer

Institute of Physiology, Justus Liebig University of Giessen, Aulweg 129, 3539, Giessen, Germany

* Corresponding author. Tel.: +49 641 99 47 221; fax: +49 641 99 47 219. Email address: yaser.abdallah{at}physiologie.med.uni-giessen.de

Received 31 October 2005; accepted 11 November 2005

See article by Ma et al. [4] (pages 57–65) in this issue.


   1. Introduction
Top
 1. Introduction
2. Reperfusion injury of...
 References
 
Protection of myocardium against lethal reperfusion injury is one of the major challenges of clinical cardiology today. Many interventions during reperfusion that may influence infarct size or improve cardiac function have been studied experimentally, but none of these has yet found its way into clinical practice. One of the oldest and most discussed interventions to modify reperfusion conditions is the use of glucose–insulin–potassium (GIK) [1], which was reported to reduce the relative in-hospital mortality risk in patients with acute myocardial infarction [2]. Administration of insulin in vivo was shown to reduce reperfusion-induced cell death through a signalling pathway comprising PI 3-kinase (PI3K)/Akt and nitric oxide synthase (eNOS) [3]. The experimental study by Ma et al. [4] in this issue of Cardiovascular Research provides an interesting contribution, focusing for the first time on the role of GIK and particularly its leading actor, insulin, for prevention of reperfusion-induced vascular injury in the heart.


   2. Reperfusion injury of cardiomyocytes and coronary vessels
Top
 1. Introduction
 2. Reperfusion injury of...
References
 
Various mechanisms contributing to cardiac reperfusion injury have been described, but protective strategies share ultimately the same goal, i.e., prevention of cell death and improvement of cardiac function. On the level of cardiac myocytes, necrotic cell death has been described as an early cause of reperfusion injury [5], but apoptosis may also contribute to cell death later during reperfusion [6]. Investigations of our own group have demonstrated the occurrence of contracture of cardiac myocytes in the early minutes of reperfusion [7,8]. Contracture development is triggered by energy recovery at still elevated cytosolic calcium levels that result from preceding ischemia. This excessive contraction of cardiac myocytes is able to induce a rapid onset of tissue necrosis [9]. A temporary pharmacological blockade of the contractile apparatus at the onset of reperfusion was shown to markedly reduce infarct size in vivo [10].

On the vascular level, vascular dysfunction in reperfused myocardial tissue was described two decades ago [11] and was attributed to structural injury of endothelial cells [12]. Adhesion of neutrophils to endothelial cells was reported to play a major role. Generation of reactive oxygen species during reperfusion is thought to trigger a death cascade, implying the expression of adhesion molecules on endothelial cell surface and the reduced production or inactivation of nitric oxide, which normally serves as a potent inhibitor of neutrophil adhesion [13]. Immunohistochemical analysis of reperfused myocardium has shown that apoptosis of endothelial cells occurs in the early phase of reperfusion and precedes apoptosis of cardiac myocytes [14].

2.1 Insulin-mediated cardiovascular protection
In various experimental studies, the PI3K/Akt signalling pathway has been identified to confer protection against reperfusion injury of the heart. It has therefore been termed a "survival pathway" [15]. This survival pathway is known to mediate cardioprotection achieved by insulin and also during the application of postconditioning, i.e. protection achieved by repetitive brief periods of ischemia applied within the first minutes of reperfusion [16]. On the one hand, activation of this signalling cascade was found to inactivate a variety of pro-apoptotic proteins such as Bad, BAX, BIM and p53 [17,18]. On the other hand, the PI3K/Akt pathway is able to activate eNOS by its phosphorylation and thus to augment the generation of NO [19]. NO was found to reduce infarct size dose-dependently when administered early during reperfusion [20] and may thus reduce acute development of necrotic cell injury. NO activates soluble guanylyl cyclase and thereby activates cGMP-dependent signalling. It has been shown that agents acting through cGMP-dependent pathways during reperfusion reduce infarct size in intact hearts [21] and attenuate hypercontracture in cardiac myocytes [22]. In these cells, the cellular mechanism of cGMP-mediated protection is likely related to the control of cytosolic calcium levels by the sarcoplasmic reticulum through an activation of the SR Ca2+ pump during the first few minutes of reperfusion [22].

The current study [4] demonstrates the ability of insulin to reduce reperfusion-induced apoptosis of coronary endothelial cells in vivo and consequently to improve endothelium-dependent relaxation of isolated coronary artery. Insulin treatment also attenuates apoptosis of cultured endothelial cells subjected to simulated ischemia and reperfusion by activation of PI3K/Akt and eNOS. The results of the study show that insulin shares the same signalling cascade for protection as previously described for myocardial tissue as a whole and for isolated cardiomyocytes, i.e. PI3K/Akt and eNOS [3]. These observations therefore indicate that this survival pathway is active also within the vascular compartment of the heart, rendering insulin even more important than before as a protective agent applicable to reperfused myocardial tissue.

In apparent contrast to this optimistic view on insulin is the recent report of a large clinical trial. This study reported that high-dose GIK had only a "neutral" effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute ST-segment elevation myocardial infarction (STEMI) [23]. The lack of effectiveness in this clinical study may have several causes. One complication was probably the frequency of hyperglycaemia, since achievement of normoglycaemia with intensive insulin therapy was shown to be indispensable to protect endothelium, preventing organ failure and death during critical illness [24]. Hyperglycaemia was shown to promote apoptotic cell death in myocardium in vivo through generation of reactive oxygen species; counteracting the beneficial effects of insulin [25]. The second shortcoming of this trial is the uncertainty about whether or not the critically narrow time frame for application of protective agents during the first few minutes of reperfusion was adequately respected.

The identification of PI3K/Akt-eNOS as a survival pathway in endothelial cells is also important because eNOS can be activated by several agents such as HMG-CoA reductase inhibitors (statins) and G-protein-coupled receptor ligands such as adenosine receptor agonists or bradykinin [26,27].


   References
Top
 1. Introduction
 2. Reperfusion injury of...
 References
 

  1. Sodi-Pallares D., Testelli M., Fishelder F. Efects of an intravenous infusion of a potassium–insulin–glucose solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol (1962) 9:166–181.[CrossRef][Web of Science][Medline]
  2. Diaz R., Paolasso E.A., Piegas L.S., Tajer C.D., Moreno M.G., Corvalan R., et al. Metabolic modulation of acute myocardial infarction. Circulation (1998) 98:2227–2234.[Abstract/Free Full Text]
  3. Gao F., Gao E., Yue T.L., Ohlstein E.H., Lopez B.L., Christopher T.A., et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation (2002) 105:1497–1502.[Abstract/Free Full Text]
  4. Ma H., Zhang H.F., Yu L., Zhang Q.J., Li J., Huo J.H., et al. Vasculoprotective effect of insulin in the ischemic/reperfused canine heart: role of Akt-stimulated NO production. Cardiovasc Res (2006) 69:57–65.[Abstract/Free Full Text]
  5. Taimor G., Lorenz H., Hofstaetter B., Schluter K.D., Piper H.M. Induction of necrosis but not apoptosis after anoxia and reoxygenation in isolated adult cardiomyocytes of rat. Cardiovasc Res (1999) 41:147–156.[Abstract/Free Full Text]
  6. Zhao Z.Q., Nakamura M., Wang N.P., Wilcox J.N., Shearer S., Ronson R.S., et al. Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res (2000) 45:651–660.[Abstract/Free Full Text]
  7. Siegmund B., Schluter K.D., Piper H.M. Calcium and the oxygen paradox. Cardiovasc Res (1993) 27:1778–1783.[Free Full Text]
  8. Piper H.M., Abdallah Y., Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res (2004) 61:3365–3671.
  9. Ganote C.E. Contraction bands necrosis and irreversible myocardial injury. J Mol Cell Cardiol (1983) 15:67–73.[Web of Science][Medline]
  10. Garcia-Dorado D., Theroux P., Duran J.M., Solares J., Alonso J., Sanz E., et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation (1992) 85:1160–1174.[Abstract/Free Full Text]
  11. Ku D.D. Coronary vascular reactivity after acute myocardial ischemia. Science (1982) 218:576–578.[Abstract/Free Full Text]
  12. Van Benthuysen K.M., McMurtry I.F., Horwitz L.D. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest (1987) 79:265–274.[Web of Science][Medline]
  13. Jordan J.E., Zhao Z.Q., Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res (1999) 43:860–878.[Abstract/Free Full Text]
  14. Scarabelli T., Stephanou A., Rayment N., Pasini E., Comini L., Curello S., et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation (2001) 104:253–256.[Abstract/Free Full Text]
  15. Hausenloy D.J., Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res (2004) 61:448–460.[Abstract/Free Full Text]
  16. Tsang A., Hausenloy D.J., Mocanu M.M., Yellon D.M. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res (2004) 95:230–232.[Abstract/Free Full Text]
  17. Kuwahara K., Saito Y., Kishimoto I., Miyamoto Y., Harada M., Ogawa E., et al. Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol (2000) 32:1385–1394.[CrossRef][Web of Science][Medline]
  18. Yamaguchi H., Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene (2001) 20:7779–7786.[CrossRef][Web of Science][Medline]
  19. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (1999) 399:597–601.[CrossRef][Medline]
  20. Wang G., Liem D.A., Vondriska T.M., Honda H.M., Korge P., Pantaleon D.M., et al. Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2005) 288:1290–1295.[CrossRef]
  21. Padilla F., Garcia-Dorado D., Agullo L., Barrabes J.A., Inserte J., Escalona N., et al. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res (2000) 51:592–600.[CrossRef][Web of Science]
  22. Abdallah Y., Gkatzoflia A., Pieper H., Zoga E., Walther S., Kasseckert S., et al. Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res (2005) 66:123–131.[Abstract/Free Full Text]
  23. Mehta S.R., Yusuf S., Diaz R., Zhu J., Pais P., Xavier D., et al. Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 293:437–446.[Abstract/Free Full Text]
  24. Langouche L., Vanhorebeek I., Vlasselaers D., Vander Perre S., Wouters P.J., Skogstrand K., et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest (2005) 115:2277–2286.[CrossRef][Web of Science][Medline]
  25. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.G. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes (2002) 51:1938–1948.[Abstract/Free Full Text]
  26. Bell R.M., Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol (2003) 41:508–515.[Abstract/Free Full Text]
  27. Bell R.M., Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol (2003) 35:185–193.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Abdallah, Y.
Right arrow Articles by Schäfer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdallah, Y.
Right arrow Articles by Schäfer, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?